Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1955 1
1962 1
1975 2
1979 2
1980 26
1981 730
1982 1854
1983 2891
1984 3882
1985 4947
1986 5405
1987 5863
1988 6029
1989 6561
1990 6942
1991 6712
1992 5897
1993 5961
1994 5896
1995 5653
1996 4958
1997 4672
1998 4704
1999 4333
2000 4516
2001 4756
2002 4336
2003 4561
2004 4764
2005 5477
2006 5650
2007 6373
2008 6856
2009 7480
2010 7626
2011 6190
2012 4871
2013 4572
2014 4610
2015 4556
2016 4663
2017 4810
2018 4388
2019 1808
2020 23
Text availability
Article attribute
Article type
Publication date

Search Results

187,658 results
Results by year
Filters applied: . Clear all
Page 1
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
Edris A, et al. Respir Res 2019. PMID 31395084 Free PMC article.
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate. PubMed and Web of Science were searched for phase II and phase III randomized clinical trials with monoclonal antibodies targeting key mediators of type 2-associated asthma. ...
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy …
[Monoclonal antibodies].
Mössner J and Neubauer A. Internist (Berl) 2019. PMID 31560084 German.
Monoclonal antibodies in severe asthma: is it worth it?
Calzetta L, et al. Expert Opin Drug Metab Toxicol 2019. PMID 31104515
Background: To date, there is the strong need to compare the efficacy across the monoclonal antibodies (mAbs) approved to treat severe asthma. ...
Background: To date, there is the strong need to compare the efficacy across the monoclonal antibodies (mAbs) approved to trea …
[Therapeutic regimens using monoclonal antibodies in gastroenterology].
Dobsch P, et al. Internist (Berl) 2019 - Review. PMID 31501913 German.
A new field has opened for targeted therapy with monoclonal antibodies of recurrent Clostridium difficile infection. In the nomenclature of monoclonal antibodies, the endings of the substances indicate the production or degree of "humanization" of the respective antibodies ("umab": fully human, recombinant antibody; "ximab": chimeric antibody with variable murine domain). ...In the current review, we provide a summary of the current applications of monoclonal antibodies in the therapeutic treatment of gastroenterological diseases....
A new field has opened for targeted therapy with monoclonal antibodies of recurrent Clostridium difficile infection. In the no …
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
Ferrari SM, et al. Int J Mol Sci 2019 - Review. PMID 31137683 Free PMC article.
Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab). ...Anti-PD-1-antibodies are more frequently associated with thyroid dysfunctions (including painless thyroiditis, hypothyroidism, thyrotoxicosis, or thyroid storm), while the most frequent irAE related to anti-CTLA-4-antibodies is hypophysitis. ...
Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimuma …
Monoclonal Antibodies: Past, Present and Future.
Posner J, et al. Handb Exp Pharmacol 2019 - Review. PMID 31820172
Monoclonal antibodies (mAbs) are immunoglobulins designed to target a specific epitope on an antigen. Immunoglobulins of identical amino-acid sequence were originally produced by hybridomas grown in culture and, subsequently, by recombinant DNA technology using mammalian cell expression systems. ...Finally, we speculate on the future with various new approaches to the development of therapeutic antibodies....
Monoclonal antibodies (mAbs) are immunoglobulins designed to target a specific epitope on an antigen. Immunoglobulins of ident
Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies.
Kumar R, et al. Int J Biol Macromol 2019 - Review. PMID 31170490
In this review we have discussed the various strategies employed for generation of monoclonal antibodies; their advantages, limitations and potential therapeutic applications. We also discuss the potential of phage display antibody libraries in isolation of monoclonal antibodies....
In this review we have discussed the various strategies employed for generation of monoclonal antibodies; their advantages, li …
Using monoclonal antibodies to investigate molecular immunology: there's more to know!
Milling S. Immunology 2019. PMID 31291693 Free PMC article.
The study of cellular and molecular immunology is almost completely dependent on monoclonal antibody technology. Despite the relatively long history of monoclonal antibodies, there is still huge potential for developing novel and transformative uses for this technology. ...Both manuscripts describe novel ways that monoclonal antibodies may be used for scientific and potentially for therapeutic benefit....
The study of cellular and molecular immunology is almost completely dependent on monoclonal antibody technology. Despite the relative …
187,658 results
Jump to page
Feedback